DK1629091T3 - Præparat indeholdende polyproteinet NS3/NS4 og polypeptidet NS5B af HCV, ekspressionsvektorer omfattende tilsvarende nukleinsyresekvenser og terapeutisk anvendelse deraf - Google Patents

Præparat indeholdende polyproteinet NS3/NS4 og polypeptidet NS5B af HCV, ekspressionsvektorer omfattende tilsvarende nukleinsyresekvenser og terapeutisk anvendelse deraf

Info

Publication number
DK1629091T3
DK1629091T3 DK04742880.0T DK04742880T DK1629091T3 DK 1629091 T3 DK1629091 T3 DK 1629091T3 DK 04742880 T DK04742880 T DK 04742880T DK 1629091 T3 DK1629091 T3 DK 1629091T3
Authority
DK
Denmark
Prior art keywords
expressed
hcv
virus
ns5b
polyprotein
Prior art date
Application number
DK04742880.0T
Other languages
English (en)
Inventor
Anne Fournillier
Genevieve Inchauspe
Jean-Daniel Abraham
Maria Dimitrova-Tchomakov
Marie Parnot
Original Assignee
Transgene Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa, Inst Nat Sante Rech Med filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1629091T3 publication Critical patent/DK1629091T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DK04742880.0T 2003-06-05 2004-06-04 Præparat indeholdende polyproteinet NS3/NS4 og polypeptidet NS5B af HCV, ekspressionsvektorer omfattende tilsvarende nukleinsyresekvenser og terapeutisk anvendelse deraf DK1629091T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0306772A FR2855758B1 (fr) 2003-06-05 2003-06-05 Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
PCT/FR2004/050214 WO2004111082A2 (fr) 2003-06-05 2004-06-04 Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique

Publications (1)

Publication Number Publication Date
DK1629091T3 true DK1629091T3 (da) 2011-08-08

Family

ID=33443147

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04742880.0T DK1629091T3 (da) 2003-06-05 2004-06-04 Præparat indeholdende polyproteinet NS3/NS4 og polypeptidet NS5B af HCV, ekspressionsvektorer omfattende tilsvarende nukleinsyresekvenser og terapeutisk anvendelse deraf

Country Status (21)

Country Link
US (3) US20060134065A1 (da)
EP (1) EP1629091B1 (da)
JP (1) JP4625803B2 (da)
KR (1) KR101158741B1 (da)
CN (1) CN100506980C (da)
AT (1) ATE508184T1 (da)
AU (1) AU2004247457B2 (da)
BR (1) BRPI0411011A (da)
CA (1) CA2528240C (da)
CY (1) CY1112081T1 (da)
DE (1) DE602004032536D1 (da)
DK (1) DK1629091T3 (da)
ES (1) ES2362578T3 (da)
FR (1) FR2855758B1 (da)
HK (1) HK1092498A1 (da)
MX (1) MXPA05013127A (da)
PL (1) PL1629091T3 (da)
PT (1) PT1629091E (da)
SI (1) SI1629091T1 (da)
WO (1) WO2004111082A2 (da)
ZA (1) ZA200509937B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6501990B1 (en) 1999-12-23 2002-12-31 Cardiac Pacemakers, Inc. Extendable and retractable lead having a snap-fit terminal connector
US7695960B2 (en) * 2003-06-05 2010-04-13 Transgene S.A. Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
WO2005105993A1 (ja) * 2004-04-30 2005-11-10 Nec Corporation Ｈｌａ結合性ペプチド、その前駆体、それをコードするｄｎａ断片および組み換えベクター
ES2291071B1 (es) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
WO2007101657A1 (en) 2006-03-09 2007-09-13 Transgene S.A. Hepatitis c virus non structural fusion protein
WO2008127308A1 (en) 2007-04-11 2008-10-23 Thomson Licensing Method and apparatus for enhancing digital video effects (dve)
EP2233575A4 (en) * 2007-12-18 2012-12-26 Univ Peking Peoples Hospital ANTI-HCV VACCINE AND METHODS OF PREPARATION AND USES THEREOF
JP5584407B2 (ja) 2008-03-07 2014-09-03 公益財団法人東京都医学総合研究所 Ｃ型肝炎ウイルス遺伝子を有する組換えワクシニアウイルス
ES2536747T3 (es) 2009-01-20 2015-05-28 Transgene Sa ICAM 1 soluble como biomarcador para predicción de respuesta terapéutica
NZ595290A (en) 2009-03-24 2012-09-28 Transgene Sa Biomarker for monitoring patients
AU2010247374A1 (en) 2009-05-12 2011-12-15 Transgene Sa Immortalized avian cell lines and use thereof
DK2452194T3 (da) 2009-07-10 2015-11-30 Transgene Sa Biomarkør til patientudvælgelse og beslægtede fremgangsmåder
AU2010275764A1 (en) 2009-07-21 2012-03-15 Transgene Sa Enzymatic composition for the digestion of chicken embryos
SG178254A1 (en) * 2009-08-07 2012-03-29 Transgene Sa Composition for treating hbv infection
WO2011073741A1 (en) 2009-12-18 2011-06-23 Transgene Sa A method and a system for automatically processing multiple measurements of biological quantifiable parameters
WO2012129295A1 (en) * 2011-03-21 2012-09-27 Vaxin Inc. Rapid and prolonged immunologic-therapeutic
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
ES2753364T3 (es) 2014-12-01 2020-04-08 Transgene Sa Formulaciones líquidas estables de virus vaccinia
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
AU2018270375A1 (en) 2017-05-15 2019-10-31 Bavarian Nordic A/S Stable virus-containing composition
AU2019336940A1 (en) 2018-09-06 2021-03-11 Bavarian Nordic A/S Storage improved poxvirus compositions
KR20220153587A (ko) 2020-03-12 2022-11-18 버베리안 노딕 에이/에스 폭스바이러스 안정성을 개선하는 조성물
CN117379542A (zh) * 2023-09-27 2024-01-12 广州佰芮慷生物科技有限公司 一种用于预防多基因型丙型肝炎病毒的腺病毒载体疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712087A (en) * 1990-04-04 1998-01-27 Chiron Corporation Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens
IL137458A0 (en) 1998-01-30 2001-07-24 Gen Hospital Corp Genetic immunization with nonstructural proteins of hepatitis c virus
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
AU6093200A (en) * 1999-07-12 2001-01-30 Saes Pure Gas, Inc. Gas purification system with an integrated hydrogen sorption and filter assembly
CA2389206C (en) * 1999-10-27 2011-01-04 Chiron Corporation Activation of hcv-specific t cells
US6986892B1 (en) * 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
FR2839722A1 (fr) * 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
US7695960B2 (en) * 2003-06-05 2010-04-13 Transgene S.A. Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

Also Published As

Publication number Publication date
JP2007527207A (ja) 2007-09-27
CA2528240A1 (fr) 2004-12-23
KR20060030476A (ko) 2006-04-10
AU2004247457A1 (en) 2004-12-23
US20060134065A1 (en) 2006-06-22
EP1629091A2 (fr) 2006-03-01
EP1629091B1 (fr) 2011-05-04
CY1112081T1 (el) 2015-11-04
SI1629091T1 (sl) 2011-07-29
CN1833022A (zh) 2006-09-13
PT1629091E (pt) 2011-07-28
CA2528240C (fr) 2013-03-05
HK1092498A1 (en) 2007-02-09
DE602004032536D1 (de) 2011-06-16
ATE508184T1 (de) 2011-05-15
WO2004111082A3 (fr) 2005-02-17
CN100506980C (zh) 2009-07-01
WO2004111082A2 (fr) 2004-12-23
US8057162B2 (en) 2011-11-15
PL1629091T3 (pl) 2011-10-31
ES2362578T3 (es) 2011-07-07
FR2855758B1 (fr) 2005-07-22
JP4625803B2 (ja) 2011-02-02
BRPI0411011A (pt) 2006-07-04
FR2855758A1 (fr) 2004-12-10
ZA200509937B (en) 2007-03-28
KR101158741B1 (ko) 2012-06-22
US8541004B2 (en) 2013-09-24
US20100008941A1 (en) 2010-01-14
AU2004247457B2 (en) 2009-02-05
US20120039938A1 (en) 2012-02-16
MXPA05013127A (es) 2006-05-25

Similar Documents

Publication Publication Date Title
HK1092498A1 (en) Composition containing the polyprotein ns3/ns4 and the polypeptide ns5b of hcv, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof
Kolykhalov et al. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo
Rosenberg Recent advances in the molecular biology of hepatitis C virus
Branch et al. The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others
Zein et al. Hepatitis C genotypes: current trends and future implications
Bukh A critical role for the chimpanzee model in the study of hepatitis C
Weiner et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity
ATE499442T1 (de) Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
DE50001673D1 (de) Hepatitis C Virus Zellkultursystem
Roussel et al. Characterization of the expression of the hepatitis C virus F protein
WO2009014216A1 (ja) Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
Luo Cellular proteins bind to the poly (U) tract of the 3′ untranslated region of hepatitis C virus RNA genome
WO2006131936B1 (en) Hepatitis c virus vaccine
AU2001290178A1 (en) A hepatitis c virus non-structural ns3/4a fusion gene
Varshney et al. A review on an update of NS5B polymerase hepatitis C virus inhibitors
Lazdina et al. Humoral and CD4+ T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein
WO2000075338A2 (en) CLONED GENONE OF INFECTIOUS HEPATITIS C VIRUS OF GENOTYPE 2a AND USES THEREOF
Karamitros et al. Detection of specific antibodies to HCV‐ARF/CORE+ 1 protein in patients treated with pegylated interferon plus ribavirin
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
Kim et al. Hepatitis C virus NS2 protein activates cellular cyclic AMP-dependent pathways
Kang et al. Monoclonal antibody recognizing N‐terminal epitope of hepatitis C virus nonstructural 5B inhibits viral RNA replication
US20020160936A1 (en) Hcv e2 protein binding agents for treatment of hepatitis c virus infection
Kumar et al. Sequence, expression and reconstitution of an HCV genome from a British isolate derived from a single blood donation
Ghasemi et al. Design, construction and evaluation of 1a/JFH1 HCV chimera by replacing the intergenotypic variable region
FAN et al. Not-So-Low-Hanging Fruit: Journey from Identifying HCV to Proving It Pathogen of Hepatitis C